SCHEMBL5494941

SCHEMBL5494941

CO/C=C/Cc1c(Cl)nc(C)nc1N(C(=O)OC(C)(C)C)c1ccc(Cl)cc1Cl

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
MT-CO2 P00403 1/20 0.32
FSCN1 Q16658 1/20 0.31
AHCY P23526 1/20 0.30
HTT P42858 2/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
IDO1 P14902 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
GLA P06280 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
XBP1 P17861 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
HSD17B10 Q99714 1/20 0.30
GAA P10253 1/20 0.30
MCOLN3 Q8TDD5 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5494943 1.00 CNR1 (0.32) CNR1CNR2MT-CO2FSCN1AHCY
SCHEMBL5489084 0.89 IDO1 (0.34) CNR1CNR2MT-CO2FSCN1AHCY
SCHEMBL3271971 0.88 RXRA (0.33) CNR1CNR2MT-CO2FSCN1HTT
SCHEMBL3277343 0.88 KMT2A (0.34) FSCN1HTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL3277335 0.88 KMT2A (0.34) FSCN1HTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL4943359 0.84 CNR1 (0.34) CNR1CNR2MT-CO2FSCN1HTT
SCHEMBL3281407 0.83 CNR1 (0.33) CNR1CNR2MT-CO2FSCN1HTT
SCHEMBL3273514 0.83 CNR1 (0.34) CNR1CNR2MT-CO2FSCN1HTT
SCHEMBL5492061 0.79 ALDH1A1 (0.34) CNR1CNR2HTTSMN1; SMN2IDO1
SCHEMBL5489054 0.78 LMNA (0.33) ALDH1A1MAPTNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279474-B2 Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) GLAXO GROUP LIMITED (GB) 2007-10-09 US disclosed
US-20040176400-A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) GLAXO GROUP LIMITED (GB) 2004-09-09 US disclosed
EP-1383747-A1 FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) GLAXO GROUP LIMITED (GB) 2004-01-28 EP disclosed
WO-2002088095-A1 FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) GLAXO GROUP LIMITED (GB) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176400-A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) CRH, CRHR1, CRHR2 CNR1 54/4885CNR2 125/4885MT-CO2 3325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.